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Cardiovascular risk reduction with liraglutide and semaglutide in patients with type 2 diabetes was
demonstrated in the LEADER (ClinicalTrials.gov: NCT01179048) and SUSTAIN 6 (ClinicalTrials.
gov: NCT01720446) cardiovascular outcome trials. This post hoc analysis assessed the impact of
diabetes duration (<5, 5 to <15, 15 to <25 and ≥25 years at baseline) on cardiorenal efficacy of
these human glucagon-like peptide-1 analogues using a Cox proportional hazards model. Propor-
tions of patients in the LEADER trial across diabetes duration strata were 15% (<5 years,
n = 1377), 50% (5 to <15 years, n = 4692), 27% (15 to <25 years, n = 2504) and 8% (≥25 years,
n = 748); corresponding proportions in the SUSTAIN-6 trial were 13% (<5 years, n = 422), 48%
(5 to <15 years, n = 1582), 30% (15 to <25 years, n = 977) and 10% (≥25 years, n = 316). Overall,
longer diabetes duration was associated with higher age; higher prevalence of females; history of
ischaemic stroke, peripheral arterial disease and insulin use; and inferior renal function. There was
an increased frequency of major adverse cardiovascular events (MACE), expanded MACE and
nephropathy events with increasing diabetes duration. Liraglutide and semaglutide consistently
reduced the risk of cardiorenal outcomes across categories of diabetes duration (P-interaction was
not significant for all endpoints analysed).
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cardiorenal, cardiovascular, diabetes duration, efficacy, LEADER, liraglutide, renal,
semaglutide, SUSTAIN 6
1 | INTRODUCTION
The duration of type 2 diabetes is an important determinant of cardio-
vascular and renal outcomes.1–5 However, less is known about
whether antihyperglycaemic agents exert a consistent benefit on
these outcomes as duration of type 2 diabetes increases. LEADER
(N = 9340) and SUSTAIN 6 (N = 3297) were large cardiovascular out-
come trials in patients with type 2 diabetes that demonstrated the
beneficial cardiovascular effects of liraglutide and semaglutide,
respectively, vs placebo, in addition to standard of care treatment.6,7
In this post hoc analysis, we evaluated the impact of diabetes duration
on key cardiovascular and renal outcomes following treatment with
these two glucagon-like peptide-1 (GLP-1) analogues.
2 | METHODS
The study designs, methods and statistical analyses have been
described previously.6,7 In both trials, the primary endpoint was a
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composite of cardiovascular death, nonfatal myocardial infarction
(MI) and nonfatal stroke (major adverse cardiovascular events
[MACE]). The key secondary endpoint (expanded MACE) also included
coronary revascularization and hospitalization for unstable angina or
heart failure. Renal outcomes were adjudicated and assessed as part
of a prespecified secondary microvascular endpoint which included
nephropathy events, defined as the new onset of macroalbuminuria,
or doubling of serum creatinine level and an estimated glomerular fil-
tration rate (eGFR) of at most 45 mL/min/1.73 m2, or the need for
continuous renal-replacement therapy, or death from renal disease.
We evaluated the efficacy of liraglutide and semaglutide for these
endpoints by diabetes duration at baseline using the following sub-
groups: <5 years, 5 to <15 years, 15 to <25 years and ≥25 years.
Hazard ratios (HRs) were estimated using a Cox proportional hazards
model with treatment and diabetes duration sub-group as factors,
and the interaction between both factors. Furthermore, for the
SUSTAIN-6 trial, the Cox proportional hazards model was stratified
for factors used for randomization.6 An interaction P value less than
0.05 was deemed significant. No adjustment for multiplicity was per-
formed. Analyses were repeated with adjustment for baseline
covariates: age, antihyperglycaemic medication, geographic region,
history of MI or stroke, renal function (eGFR), sex and smoking status.
Sensitivity analyses were also performed with four sub-groups based
on quartiles of diabetes duration.
3 | RESULTS
3.1 | Baseline characteristics
In the LEADER trial, 15% (n = 1377), 50% (n = 4692), 27% (n = 2504)
and 8% (n = 748) of patients had baseline diabetes duration of <5,
5 to <15, 15 to <25 and ≥25 years, respectively; corresponding pro-
portions in the SUSTAIN-6 trial were 13% (n = 422), 48% (n = 1582),
30% (n = 977) and 10% (n = 316) for sub-groups <5 years, 5 to
<15 years, 15 to <25 years and ≥25 years, respectively. Baseline
characteristics of patients according to duration of diabetes are shown
in Table 1A and B. Across the diabetes duration strata in the LEADER
and SUSTAIN 6 trials, mean diabetes duration was 3 years in the
<5 years sub-group, 10 years in the 5 to <15 years sub-group,
19 years in the 15 to <25 years sub-group and 31 years in the
>25 years sub-group (Table 1). Mean glycated haemoglobin (HbA1c)
at baseline was similar across the strata of diabetes duration in both
trials (8.4%-8.8%), with the lowest values recorded in the <5 years
sub-groups (Table 1). Increasing diabetes duration was associated with
increasing age, higher prevalence of females, modestly higher systolic
blood pressure and greater insulin use (Table 1). The prevalence of
some macrovascular complications, including peripheral artery disease,
ischaemic stroke, carotid artery stenosis and coronary artery bypass
graft (CABG) surgery was higher with longer duration of diabetes;
however, this was not observed for MI, heart failure and percutaneous
coronary intervention (Table 1). Renal function (eGFR) at baseline
worsened with increasing diabetes duration and, correspondingly, the
prevalence of moderate or severe renal disease, including end-stage
renal disease, increased with longer duration of diabetes (Table 1).
3.2 | Risk of cardiorenal events according to
diabetes duration regardless of treatment
In the LEADER trial, MACE occurred more frequently with increas-
ing diabetes duration (<5 years: 167 patients [12.1%], 3.1
events/100 patient years of observation [PYO]; 5 to <15 years:
631 patients [13.4%], 3.5 events/100 PYO; 15 to <25 years:
383 patients [15.3%], 4.1 events/100 PYO; ≥25 years: 116 patients
[15.5%], 4.1 events/100 PYO). Compared with patients with diabe-
tes duration of <5 years, HRs for MACE (95% confidence interval
[CI]) were 1.13 (0.95; 1.34), 1.31 (1.09; 1.57) and 1.30 (1.03; 1.65) in
patients with diabetes duration of 5 to <15 years, 15 to <25 years
and ≥25 years, respectively. Similar results were obtained for the
expanded MACE outcome (<5 years: 273 patients [19.8%], 5.1
events/100 PYO; 5 to <15 years: 981 patients [20.9%], 5.5 events/100
PYO; 15 to <25 years: 566 patients [22.6%], 6.0 events/100 PYO;
≥25 years: 184 patients [24.6%], 6.5 events/100 PYO). Compared with
patients with diabetes duration of <5 years, HRs for expanded MACE
(95% CI) were 1.06 (0.93; 1.21), 1.17 (1.02; 1.36) and 1.27 (1.05; 1.53)
in patients with diabetes duration of 5 to <15 years, 15 to <25 years
and ≥25 years, respectively. Incidence rates for cardiovascular death
were 1.0, 1.3, 1.7 and 1.8 per 100 PYO, and were 1.0, 1.5, 2.2 and 2.6
per 100 PYO for nephropathy, according to increasing duration of
diabetes.
In the SUSTAIN 6 trial, MACE occurred most frequently in the
sub-group of patients with the longest duration of diabetes, but the
pattern of increasing risk of MACE with diabetes duration observed in
the LEADER trial was less apparent (<5 years: 35 patients [8.3%],
4.0 events/100 PYO; 5 to <15 years: 109 patients [6.9%],
3.3 events/100 PYO; 15 to <25 years: 77 patients [7.9%], 3.8
events/100 PYO; ≥25 years: 33 patients [10.4%], 5.1 events/100
PYO). Compared with patients with diabetes duration of <5 years,
HRs for MACE (95% CI) were 0.80 (0.55; 1.20), 0.83 (0.55; 1.27) and
1.03 (0.63; 1.70) in patients with diabetes duration of 5 to <15 years,
15 to <25 years and ≥25 years, respectively,. The frequency of
expanded MACE did, however, increase with diabetes duration
(<5 years: 51 patients [12.1%], 5.9 events/100 PYO; 5 to <15 years:
212 patients [13.4%], 6.5 events/100 PYO; 15 to <25 years:
145 patients [14.8%], 7.2 events/100 PYO; ≥25 years: 55 patients
[17.4%], 8.6 events/100 PYO). Compared with patients with diabetes
duration of <5 years, HRs (95% CI) for expanded MACE were 1.11
(0.82; 1.53), 1.15 (0.83; 1.61) and 1.29 (0.87; 1.91) in patients with
diabetes duration of 5 to <15 years, 15 to <25 years and ≥25 years.
Incidence rates for cardiovascular death were 1.4, 1.2, 1.3 and 2.0 per
100 PYO, and were 2.2, 1.8, 3.1 and 3.6 per 100 PYO for nephropa-
thy, according to increasing duration of diabetes. Results were similar
in the LEADER and SUSTAIN 6 trials in analyses adjusted for baseline
covariates and in analyses using sub-groups based on quartiles of dia-
betes duration (data not shown).
3.3 | Cardiorenal efficacy of liraglutide and
semaglutide according to diabetes duration
Figure 1 describes cardiorenal events in patients treated with
liraglutide and semaglutide in the LEADER and SUSTAIN 6 trials,
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TABLE 1 Baseline characteristics according to duration of diabetes in the (A) LEADER and (B) SUSTAIN 6 trials
Characteristic
(A)
Duration of diabetes, years
<5
(n = 1377)
5 to <15
(n = 4692)
15 to <25
(n = 2504)
≥25
(n = 748)
Age, years, mean (SD) 62.0 (7.1) 63.7 (7.0) 65.5 (7.1) 68.1 (7.4)
Male, n (%) 930 (67.5) 3060 (65.2) 1564 (62.5) 436 (58.3)
Female, n (%) 447 (32.5) 1632 (34.8) 940 (37.5) 312 (41.7)
HbA1c, %, mean (SD) 8.4 (1.5) 8.7 (1.5) 8.8 (1.5) 8.8 (1.5)
Duration of diabetes, years, mean (SD) 2.7 (1.4) 9.7 (2.7) 18.9 (2.7) 30.7 (5.7)
CV historya
Myocardial infarction, n (%) 465 (33.8) 1447 (30.8) 677 (27.0) 214 (28.6)
Heart failure (NYHA II-III), n (%) 256 (18.6) 663 (14.1) 296 (11.8) 87 (11.6)
Percutaneous coronary intervention, n (%) 377 (27.4) 1283 (27.3) 683 (27.3) 220 (29.4)
Coronary artery bypass graft, n (%) 183 (13.3) 740 (15.8) 430 (17.2) 177 (23.7)
Ischaemic stroke, n (%) 150 (10.9) 505 (10.8) 280 (11.2) 102 (13.6)
Peripheral arterial disease, n (%) 139 (10.1) 546 (11.6) 356 (14.2) 123 (16.4)
Carotid artery stenosis, n (%) 86 (6.2) 339 (7.2) 187 (7.5) 85 (11.4)
>50% stenosis of major artery, n (%) 331 (24.0) 1179 (25.1) 650 (26.0) 212 (28.3)
LV systolic dysfunction, n (%) 176 (12.8) 511 (10.9) 252 (10.1) 58 (7.8)
LV diastolic dysfunction, n (%) 263 (19.1) 811 (17.3) 401 (16.0) 104 (13.9)
Diabetes medication
Oral antihyperglycaemic, n (%) 1214 (88.2) 4265 (90.9) 2153 (86.0) 595 (79.5)
Metformin, n (%) 1055 (76.6) 3731 (79.5) 1847 (73.8) 501 (67.0)
SU, n (%) 596 (43.3) 2601 (55.4) 1231 (49.2) 295 (39.4)
Insulin, n (%) 269 (19.5) 1900 (40.5) 1498 (59.8) 495 (66.2)
Renal function
eGFR, mL/min/1.73 m2, mean (SD) 86.0 (24.9) 82.4 (26.7) 76.4 (28.4) 70.9 (27.7)
Moderate or severe renal disease, n (%) 189 (13.7) 957 (20.4) 732 (29.2) 272 (36.0)
CV medication
ACEi, n (%) 722 (52.4) 2429 (51.8) 1252 (50.0) 354 (47.3)
ARB, n (%) 375 (27.2) 1482 (31.6) 839 (33.5) 273 (36.5)
Lipid-lowering therapies, n (%) 995 (72.3) 3551 (75.7) 1924 (76.8) 596 (79.7)
Anti-platelet agents, n (%) 905 (65.7) 3131 (66.7) 1743 (69.6) 535 (71.5)
Other risk factors
Systolic BP, mm Hg, mean (SD) 134.5 (16.9) 135.5 (17.3) 137.1 (18.3) 137.1 (19.8)
Diastolic BP, mm Hg, mean (SD) 79.3 (10.0) 77.7 (9.9) 75.8 (10.3) 73.7 (11.0)
BMI, kg/m2, mean (SD) 33.2 (6.4)
n = 1376
32.7 (6.2)
n = 4689
32.1 (6.4)
n = 2500
31.5 (6.1)
n = 747
Characteristic
(B)
Duration of diabetes, years
<5
(n = 422)
5 to <15
(n = 1582)
15 to <25
(n = 977)
≥25
(n = 316)
Age, years, mean (SD) 62.0 (7.7) 63.9 (7.0) 65.8 (7.1) 68.3 (7.9)
Male, n (%) 267 (63.3) 971 (61.4) 587 (60.1) 177 (56.0)
Female, n (%) 155 (36.7) 611 (38.6) 390 (39.9) 139 (44.0)
HbA1c, %, mean (SD) 8.5 (1.5) 8.7 (1.5) 8.7 (1.4) 8.8 (1.4)
Duration of diabetes, years, mean (SD) 3.0 (1.5) 10.2 (2.8) 19.1 (2.8) 30.7 (5.5)
CV historya
Myocardial infarction, n (%) 165 (39.1) 518 (32.7) 292 (29.9) 97 (30.7)
Heart failure (NYHA II-III), n (%) 105 (24.9) 289 (18.3) 133 (13.6) 47 (14.9)
Percutaneous coronary intervention, n (%) 155 (36.7) 466 (29.5) 288 (29.5) 103 (32.6)
Coronary artery bypass graft, n (%) 63 (14.9) 249 (15.7) 180 (18.4) 85 (26.9)
Ischaemic stroke, n (%) 42 (10.0) 191 (12.1) 107 (11.0) 43 (13.6)
Peripheral arterial disease, n (%) 38 (9.0) 206 (13.0) 150 (15.4) 59 (18.7)
(Continues)
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respectively, according to increasing duration of diabetes. Both GLP-1
analogues exhibited consistent benefits on the primary MACE end-
point, and on expanded MACE, cardiovascular death and nephropathy
across diabetes duration strata, with no evidence of statistical hetero-
geneity (Pinteraction = not significant for all endpoints) (Figure 1). Similar
results were obtained in analyses adjusted for baseline covariates
(data not shown) and in analyses using sub-groups based on quartiles
of diabetes duration (Figure S1).
4 | DISCUSSION
The management of long-standing type 2 diabetes remains an impor-
tant challenge. In addition to the difficulties of maintaining glycaemic
control, long duration of diabetes is associated with an increase in car-
diovascular complications and progressive renal decline, which in turn
contribute to heightened rates of morbidity and mortality in these
patients.1–5 While much is known about the association of diabetes
duration with rates of complications, considerably less is known about
the details of the efficacy and safety of antihyperglycaemic agents,
such as GLP-1 analogues, as diabetes duration increases, particularly if
GLP-1 analogues have consistent cardiorenal efficacy across different
durations of type 2 diabetes.
In an attempt to specifically address this subject, we conducted a
post hoc analysis of two large cardiovascular outcome trials of
liraglutide (LEADER)7 and semaglutide (SUSTAIN 6).6 Both trials dem-
onstrated benefits of these GLP-1 analogues compared with placebo
on the primary outcome of MACE (HR [95% CI]: 0.87 [0.78; 0.97] with
liraglutide in LEADER and 0.74 [0.58; 0.95] with semaglutide in SUS-
TAIN 6).6,7 Furthermore, liraglutide was associated with a significant
reduction in the risk of cardiovascular death (HR [95% CI]: 0.78 [0.66;
0.93]),7 with consistent benefits observed in patients with atheroscle-
rotic vascular disease, with or without a prior ischaemic event.8,9 Sev-
eral mechanisms, including anti-inflammatory and anti-atherosclerotic
effects,10–12 have been suggested to mediate the cardiovascular ben-
efits of GLP-1 analogues that are observed in addition to those of
conventional risk reduction therapies including lipid lowering.13
Our post hoc analyses of the LEADER and SUSTAIN 6 trials con-
firm that increasing duration of diabetes is associated with increased
rates of cardiorenal outcomes. At baseline, increasing duration of dia-
betes was associated with a greater prevalence of peripheral artery
disease, ischaemic stroke, history of CABG and renal disease. During
TABLE 1 (Continued)
Characteristic
(B)
Duration of diabetes, years
<5
(n = 422)
5 to <15
(n = 1582)
15 to <25
(n = 977)
≥25
(n = 316)
Carotid artery stenosis, n (%) 35 (8.3) 129 (8.2) 95 (9.7) 35 (11.1)
>50% stenosis of major artery, n (%) 165 (39.1) 557 (35.2) 327 (33.5) 118 (37.3)
LV systolic dysfunction, n (%) 71 (16.8) 192 (12.1) 108 (11.1) 31 (9.8)
LV diastolic dysfunction, n (%) 108 (25.6) 342 (21.6) 170 (17.4) 50 (15.8)
Diabetes medication
Oral antihyperglycaemic, n (%) 355 (84.1) 1389 (87.8) 795 (81.4) 237 (75.0)
Metformin, n (%) 311 (73.7) 1228 (77.6) 688 (70.4) 190 (60.1)
SU, n (%) 180 (42.7) 737 (46.6) 386 (39.5) 107 (33.9)
Insulin, n (%) 98 (23.2) 676 (42.7) 568 (58.1) 209 (66.1)
Renal function
eGFR, mL/min/1.73 m2, mean (SD) 83.4 (25.3) 79.0 (26.4) 71.9 (26.2) 65.0 (24.3)
Moderate or severe renal disease,b n (%) 74 (17.5) 389 (24.6) 330 (33.8) 146 (46.2)
CV medication
ACEi, n (%) 228 (54.0) 811 (51.3) 459 (47.0) 144 (45.6)
ARB, n (%) 104 (24.6) 522 (33.0) 358 (36.6) 127 (40.2)
Lipid-lowering therapies, n (%) 305 (72.3) 1196 (75.6) 760 (77.8) 260 (82.3)
Anti-platelet agents, n (%) 311 (73.7) 1158 (73.2) 695 (71.1) 245 (77.5)
Other risk factors
Systolic BP, mm Hg, mean (SD) 133.3 (15.9) 135.4 (17.1) 136.4 (17.3) 137.5 (18.4)
Diastolic BP, mm Hg, mean (SD) 79.01 (9.8) 77.7 (9.9) 76.1 (10.1) 74.1 (9.8)
BMI, kg/m2, mean (SD) 33.6 (6.4) 33.2 (6.0)
n = 1578
32.3 (6.5)
n = 974
31.6 (5.9)
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CV, cardio-
vascular; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; LV, left ventricular; NYHA, New York Heart Association; SD, standard
deviation; SU, sulphonylurea.
Full analysis set, unless otherwise indicated. P values were derived using chi-square test for differences between diabetes duration categories regardless of
treatment group.
aBased on medical history as reported by the trial investigator for each patient.
bIncludes end-stage renal disease.
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the trials, there was a trend for higher rates of MACE, expanded
MACE, cardiovascular death and nephropathy with longer duration of
type 2 diabetes. Importantly, both liraglutide and semaglutide
exhibited consistent benefits on these cardiorenal endpoints
irrespective of the duration of diabetes. For liraglutide, this finding of
consistent benefits in apparently higher- and lower-risk patients is not
concordant with the pre-specified sub-group analysis of the LEADER
trial, which showed a significant interaction in favour of patients with
FIGURE 1 Risk of cardiorenal events in patients treated with liraglutide (upper panel) or semaglutide (lower panel) vs placebo, by diabetes
duration at baseline. LEADER total population: 9340. LEADER total population with diabetes duration available: 9321. SUSTAIN 6 total
population (all patients with diabetes duration available): 3297. MACE comprised CV death, nonfatal MI and nonfatal stroke. Expanded MACE
comprised MACE components plus coronary revascularization and hospitalization for unstable angina or heart failure. Nephropathy events were
defined as new onset of macroalbuminuria or doubling of serum creatinine level and eGFR ≤45 mL/min/1.73 m2, the need for continuous renal-
replacement therapy or death from renal disease. Abbreviations: CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration
rate; GLP-1, glucagon-like peptide-1; MACE, major adverse cardiovascular events; N, number of patients with event; R, events per 100 patient
years of observation
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established CVD.7 A more recent post hoc analysis of the LEADER
trial showed that liraglutide reduced CV events both in patients with a
history of MI or stroke and in those with established atherosclerotic
cardiovascular disease without MI or stroke, indicating that the CV
benefits of liraglutide are maintained across a clinically relevant con-
tinuum of risk in type 2 diabetes with atherosclerosis or prior
ischaemic events.9 However, in the current analysis, patients with a
shorter duration of diabetes had a higher prevalence of heart failure,
myocardial infarction, and systolic or diastolic dysfunction at baseline,
compared with those with a longer duration of diabetes, indicating
previous events. Hence, it is difficult to make a direct comparison with
the previously reported results.
The similar designs of the LEADER and SUSTAIN 6 trials facilitate
comparison of our findings across the two trials, but this may also limit
our findings to the patients enrolled in these trials. While not all
glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demon-
strated cardiorenal efficacy, it could be of interest for future analyses
to examine the impact of diabetes duration on the cardiorenal effects
of GLP-1RAs across a wider range of trials and patients.
In summary, our analyses provide reassurance that the cardiorenal
efficacy and safety of liraglutide and semaglutide are maintained over
a broad range of patients, from those who are relatively newly diag-
nosed to those with long-standing type 2 diabetes.
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